Investor’s Alert: MGM Resorts International (NYSE:MGM); The Procter & Gamble Company (NYSE:PG) And HemispherxBioPharma, Inc (NYSEMKT:HEB)

Boston, MA, 03/25/2014  (usastockreports) – MGM Resorts International (NYSE:MGM) has confirmed that it will contribute its bit in celebrating the Earth Hour day. The company renowned for its resorts said that it will partake in the good cause and would dim lights at its resorts between 8:30 PM to 9:30 PM on Saturday, March 29. The company’s exterior lights, rooftop signage, front lights and marquees will be completely turned off during the time. The other popular landmarks across the globe partaking in the celebration are BurjKhalifa, Eiffel Tower and the Empire State Building. Every year, Earth Hour is celebrated across the globe to mark the day with the intention to promote energy conservation. As a participant in the initiative, MGM Resorts International (NYSE:MGM) has been able to save 420 million Kw hrs of energy in the last five years, which is equivalent to 37,000 homes on an annual basis.

The Procter & Gamble Company (NYSE:PG) was quick to recover from its early trade losses on Monday. However, there was no specific news related to the company to drive its stocks higher and the movement reflected a general outlook. The Procter & Gamble Company (NYSE:PG) has ample of growth prospects, but it has to thrive in a business environment of emerging markets, which does not offer much opportunity for high growth.

HemispherxBioPharma, Inc (NYSEMKT:HEB) presented its Phase III clinical interpretations at the 11th Biennial International Research and Clinical Conference that took place in San Francisco. The trial was undertaken at twelve centers by the researchers having expertise in fatigue, caused after exertion. The statistics on the experimental immunotherapeutic, Rintatolimod, included a re-examination of the primary as well as secondary endpoints, which involves dichotomization of patientreplies. The immunotherapeutic generated remarkable results in ET and life indicators quality in a set of patients with CFS. Moreover, Rintatolimod also lowered deterioration in ET as against placebo.

Like it? Share it!

Leave A Response